Analyst Price Targets — TMDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 12:23 pm | — | Canaccord Genuity | $148.00 | $125.04 | TheFly | TransMedics price target raised to $148 from $147 at Canaccord |
| December 8, 2025 12:35 pm | — | Needham | $166.00 | $136.51 | TheFly | TransMedics price target raised to $166 from $148 at Needham |
| December 2, 2025 11:39 am | — | Morgan Stanley | $135.00 | $150.42 | TheFly | TransMedics price target raised to $135 from $123 at Morgan Stanley |
| October 30, 2025 11:14 am | Matt O'Brien | Piper Sandler | $140.00 | $134.32 | TheFly | TransMedics price target lowered to $140 from $145 at Piper Sandler |
| October 30, 2025 10:27 am | Jason Mills | Canaccord Genuity | $147.00 | $134.32 | StreetInsider | TransMedics Group (TMDX) PT Raised to $147 at Canaccord Genuity |
| October 23, 2025 9:53 am | — | Needham | $148.00 | $119.54 | TheFly | TransMedics upgraded to Buy from Hold at Needham |
| October 13, 2025 9:20 am | — | Jefferies | $145.00 | $107.29 | TheFly | TransMedics initiated with a Buy at Jefferies |
| October 7, 2025 10:42 am | — | Evercore ISI | $155.00 | $113.93 | TheFly | TransMedics added to 'Tactical Underperform' list at Evercore ISI |
| December 11, 2024 11:58 am | David Rescott | Robert W. Baird | $120.00 | $67.36 | TheFly | TransMedics price target lowered to $120 from $150 at Baird |
| December 11, 2024 11:46 am | Matt O'Brien | Piper Sandler | $90.00 | $67.36 | TheFly | TransMedics price target lowered to $90 from $110 at Piper Sandler |
Latest News for TMDX
TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended…
TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.
TransMedics (TMDX) shares rose 6.69% in pre-market trading after the company reported fourth-quarter 2025 results. Revenue for the quarter reached $160.8 millio
Axon climbs after forecast beats, MercadoLibre e-commerce volumes soar, and more
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TMDX.
U.S. House Trading
No House trades found for TMDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.